Diagnosis Value of Tumor-associated Auto-antibodies Combined with Low-dose Spiral Computed Tomography in Early Lung Cancer Screening

ZHAN Na; XU Wei; ZENG Zhi; DONG Liling

doi:10.3971/j.issn.1000-8578.2022.22.0060

Cancer Research on Prevention and Treatment > 2022 > 49(9): 908-912. > DOI: 10.3971/j.issn.1000-8578.2022.22.0060

ZHAN Na, XU Wei, ZENG Zhi, DONG Liling. Diagnosis Value of Tumor-associated Auto-antibodies Combined with Low-dose Spiral Computed Tomography in Early Lung Cancer Screening[J]. Cancer Research on Prevention and Treatment, 2022, 49(9): 908-912. DOI: 10.3971/j.issn.1000-8578.2022.22.0060

Citation:

PDF (10159 KB)

Diagnosis Value of Tumor-associated Auto-antibodies Combined with Low-dose Spiral Computed Tomography in Early Lung Cancer Screening

ZHAN Na^{1, 2},
XU Wei^2, ,,
ZENG Zhi^{1, 2},
DONG Liling³

1.
Department of Pathology, Renmin Hospital of Wuhan University, Wuhan 430060, China
2.
Medical Examination Center, Renmin Hospital of Wuhan University, Wuhan 430060, China
3.
Medical Examination Center, Union Jiangnan Hospital, Huazhong University of Science and Technology, Wuhan 430200, China

Funding:

Dr. Chinese Health Management Science Research Fund 2021HX0019

More Information

Corresponding author:
XU Wei, E-mail: 1535065582@qq.com
Received Date: January 17, 2022
Revised Date: May 23, 2022
Available Online: January 12, 2024

Graphical Abstract

Abstract

Abstract

Objective
To investigate the application value of serum auto-antibody detection combined with low-dose spiral computed tomography (LDCT) in early lung cancer screening.
Methods
From 12568 medical examination crowd (7453 males and 5115 females), 1324 people with high-risk cases of lung cancer in our medical examination center were divided randomly into three groups (LDCT, serum auto-antibody, and serum auto-antibody combined with LDCT groups). All people in this research were screened by chest X-ray. Follow-up was conducted for one year, and the positive screening and diagnosis rates of early lung cancer screening were compared between these groups of high-risk people with lung cancer.
Results
The positive screening and diagnostic rates of high-risk lung cancer in the serum auto-antibody combined with LDCT group was significantly higher those that in other two groups (P < 0.001). The specificity and sensitivity of serum auto-antibody combined with LDCT group were 89.1% and 88.4%, respectively; the area under the ROC curve was 0.863.
Conclusion
Serum auto-antibody detection combined with low-dose spiral CT can significantly improve the positive screening rate of lung cancer in high-risk populations, providing a strong theoretical support for lung cancer screening pathway.
- Serum autoantibody detection,
- Low-dose spiral CT,
- Early stage lung cancer,
- High-risk population

FullText(HTML)

Competing interests: The authors declare that they have no competing interests.

References (22)

References

[1]	Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33. doi: 10.3322/caac.21708
[2]	Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018, 391(10125): 1023-1075. doi: 10.1016/S0140-6736(17)33326-3
[3]	Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer[J]. J Thorac Oncol, 2016, 11(1): 39-51. doi: 10.1016/j.jtho.2015.09.009
[4]	National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening[J]. N Engl J Med, 2011, 365(5): 395-409. doi: 10.1056/NEJMoa1102873
[5]	Tang ZM, Ling ZG, Wang CM, et al. Serum tumor-associated autoantibodies as diagnostic biomarkers for lung cancer: A systematic review and meta-analysis[J]. PLoS One, 2017, 12(7): e182117.
[6]	杨景伟, 尹德军, 刘玉霞, 等. 血清自身抗体检测联合低剂量螺旋CT在早期肺癌筛查中的临床价值[J]. 系统医学, 2019, 4(17): 10-13. https://www.cnki.com.cn/Article/CJFDTOTAL-XTYX201917004.htm Yang JW, Yin DJ, Liu YX, et al. Clinical value of serum autoantibody detection combined with low-dose spiral CT in early lung cancer screening[J]. Xi Tong Yi Xue, 2019, 4(17): 10-13. https://www.cnki.com.cn/Article/CJFDTOTAL-XTYX201917004.htm
[7]	Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J (Engl), 2022, 135(5): 584-590. doi: 10.1097/CM9.0000000000002108
[8]	Wang Q, Wang Q, Wang SF, et al. Oral Chinese herbal medicine as maintenance treatment after chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis[J]. Curr Oncol, 2017, 24(4): e269-e276. doi: 10.3747/co.24.3561
[9]	Petpiroon N, Bhummaphan N, Tungsukruthai S, et al. Chrysotobibenzyl inhibition of lung cancer cell migration through Caveolin-1-dependent mediation of the integrin switch and the sensitization of lung cancer cells to cisplatin-mediated apoptosis[J]. Phytomedicine, 2019, 58: 152888. doi: 10.1016/j.phymed.2019.152888
[10]	Kauczor HU, Bonomo L, Gaga M, et al. ESR/ERS white paper on lung cancer screening[J]. Eur Radiol, 2015, 25(9): 2519-2531. doi: 10.1007/s00330-015-3697-0
[11]	Reck M, Rabe KF. Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2017, 377(9): 849-861. doi: 10.1056/NEJMra1703413
[12]	Guo W, Hu M, Wu J, et al. Gprc5a depletion enhances the risk of smoking-induced lung tumorigenesis and mortality[J]. Biomed Pharmacother, 2019, 114: 108791. doi: 10.1016/j.biopha.2019.108791
[13]	Riihimäki M, Hemminki A, Fallah M, et al. Metastatic sites and survival in lung cancer[J]. Lung Cancer, 2014, 86(1): 78-84. doi: 10.1016/j.lungcan.2014.07.020
[14]	Ullah MF, Aatif M. The footprints of cancer development: Cancer biomarkers[J]. Cancer Treat Rev, 2009, 35(3): 193-200. doi: 10.1016/j.ctrv.2008.10.004
[15]	Jett J, Healey G, Macdonald I, et al. Determination of the Detection Lead Time for Autoantibody Biomarkers in Early Stage Lung Cancer Using the UKCTOCS Cohort[J]. J Thorac Oncol, 2017, 122(11): S2170.
[16]	Brims F, McWilliams A, Fong K. Lung cancer screening in Australia: progress or procrastination?[J]. Med J Aust, 2016, 204(1): 4-5. doi: 10.5694/mja15.01109
[17]	Qiu J, Choi G, Li L, et al. Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera[J]. J Clin Oncol, 2008, 26(31): 5060-5066. doi: 10.1200/JCO.2008.16.2388
[18]	Leavitt J, Pangilinan J. 2019 World conference of lung cancer round-up[J]. Oncology (Williston Park), 2019, 33(11): 687519.
[19]	中华医学会肿瘤学分会, 中华医学会杂志社. 中华医学会肿瘤学分会肺癌临床诊疗指南(2021版)[J]. 中华肿瘤杂志, 2021, 43(6): 591-621. doi: 10.3760/cma.j.cn112152-20210207-00118 Oncology Society of Chinese Medical Association, Chinese Medical Association Publishing House. Oncology Society of Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2021 edition)[J]. Zhonghua Zhong Liu Za Zhi, 2021, 43(6): 591-621. doi: 10.3760/cma.j.cn112152-20210207-00118
[20]	Ren S, Zhang S, Jiang T, et al. Early detection of lung cancer by using an autoantibody panel in Chinese population[J]. Oncoimmunology, 2018, 7(2): e1384108. doi: 10.1080/2162402X.2017.1384108
[21]	Massion PP, Healey GF, Peek LJ, et al. Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer[J]. J Thorac Oncol, 2017, 12(3): 578-584. doi: 10.1016/j.jtho.2016.08.143
[22]	Du Q, Yu R, Wang H, et al. Significance of tumor-associated autoantibodies in the early diagnosis of lung cancer[J]. Clin Respir J, 2018, 12(6): 2020-2028. doi: 10.1111/crj.12769

[1]	HE Jiawei, CAO Longnyu, TANG Mengyuan, CUI Hongquan. Causal Relationships Between Immune Cells and Risk of Gastric Cancer: A Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2025, 52(2): 172-176. DOI: 10.3971/j.issn.1000-8578.2025.24.0438
[2]	WU Tong, GAO Fei, TENG Fei, ZHANG Qiaoli. Genetic Determinants of Immune Cells and Hepatocellular Carcinoma Risk: A Bioinformatics and Bidirectional Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2025, 52(1): 42-51. DOI: 10.3971/j.issn.1000-8578.2025.24.0562
[3]	YUAN Chendong, SHU Xufeng, WANG Xiaoqiang, JIE Zhigang. Relationship Between High-Density Lipoprotein Cholesterol and Colorectal Cancer—A Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2024, 51(10): 847-851. DOI: 10.3971/j.issn.1000-8578.2024.24.0153
[4]	GONG Wanli, HOU Yaqi, WANG Yue, LI Yuan, QI Rongxuan, YU Qi, ZHANG Juan. Immune Cell-Mediated Effect of Lipid Profile on Colorectal Cancer: A Two-Step, Two-Sample Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2024, 51(10): 831-839. DOI: 10.3971/j.issn.1000-8578.2024.24.0284
[5]	LIU Jingting, ZHOU Yawei, KONG Lingguo, WANG Qiandan, SU Tianxiong, PEI Jianying, LI Yan. Causal Association Between Immune Cells and Cervical Cancer: A Two-Sample Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2024, 51(9): 772-778. DOI: 10.3971/j.issn.1000-8578.2024.24.0037
[6]	WANG Yuanhang, SONG Zhiyuan, LU Ping, ZHANG Min. Analysis of Association Between Immune Cells and Breast Cancer Based on Two-sample Mendelian Randomization Method[J]. Cancer Research on Prevention and Treatment, 2024, 51(5): 348-352. DOI: 10.3971/j.issn.1000-8578.2024.23.1125
[7]	LIU Longjiao, YAO Yufeng. Circulating Inflammatory Proteins in Relation to Risk of Breast Cancer: A Two-sample Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2024, 51(5): 342-347. DOI: 10.3971/j.issn.1000-8578.2024.23.1344
[8]	WEI Wei, LIU Ming, XU Jianguo, GAO Ya, SHEN Caiyi, TIAN Jinhui. Causal Relationship Between Acromegaly and Colon Cancer: A Two-sample Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2023, 50(12): 1209-1213. DOI: 10.3971/j.issn.1000-8578.2023.23.0507
[9]	WANG Mengyuan, XU Hengmin, WANG Jingxuan, PAN Kaifeng, LI Wenqing. Mendelian Randomization Analysis of Research on Risk Factors for Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2023, 50(5): 470-476. DOI: 10.3971/j.issn.1000-8578.2023.22.1411
[10]	Xin-ying ZHOU, Hu ZHANG, Hai-yan DAI. Mendelian randomization analysis of the correlation between interleukin and the risk of gynecological tumors[J]. Cancer Research on Prevention and Treatment. DOI: 10.3971/j.issn.1000-8578.20240994

Cited By

Cited by

Periodical cited type(13)

1.	吴杨，隋雨桐，李斌鹏，韩路拓，姜家康. 激酶/转录因子信号通路调控肺癌机制及中医药干预的研究进展. 世界中医药. 2025(01): 142-147+154 .
2.	曹家瑞，冯博，马纯政，陈伟霞，喻江凡，曹莎莎，张振予，欧阳文慧. 中医药调控JAK/STAT信号通路干预肺癌的机制研究进展. 中国实验方剂学杂志. 2025(09): 265-276 .
3.	梁帅，尹怡，刘湘花，汪保英，骆文龙，龙云凯，任振杰，王祥麒. 升降理肺消瘤汤对Lewis肺癌小鼠免疫炎性反应和JAK2/STAT3信号通路的影响. 辽宁中医药大学学报. 2024(04): 27-32 .
4.	张彩蝶，靳艳，张德德. 润肺益肾饮对肺癌荷瘤大鼠的抑瘤作用和肿瘤免疫微环境的影响. 天津医药. 2024(04): 362-366 .
5.	孙喜，王召路，贾谨睿，王梦洋，孙润卓，王鹏，史新娥. 虫草素及其在生猪养殖中的应用. 畜牧兽医杂志. 2024(04): 1-7 .
6.	兰春燕，杨小兰，贺雪峰，赵丹，杨海燕. 甘草苷对胃癌荷瘤小鼠免疫功能的调节作用及机制研究. 中国药房. 2024(15): 1862-1867 .
7.	张景淇，郭静，陈娅欣，蒲玥衡，向俊杰. 中药调控肺癌相关信号通路研究进展. 中国实验方剂学杂志. 2024(19): 233-244 .
8.	张孟恩，韩睿，徐超，庞训胜，王世琴. 地顶孢霉培养物在反刍动物生产中的应用研究进展. 中国畜牧杂志. 2024(12): 70-74 .
9.	高铭，丁美灵，雷紫琴，胡靖文，栾飞，曾南. 荆防败毒散及其中成药制剂研究进展. 中药药理与临床. 2023(05): 112-118 .
10.	朱亚兰，吕世文，曾晨欣，徐媛青. 苍术素对非小细胞肺癌细胞上皮间质转化的影响及机制研究. 浙江医学. 2023(10): 1013-1018 .
11.	陈才伟，陈家亮，李华娟，方芳，文方玲. 虫草素调节MAPK/AP-1信号通路对慢性阻塞性肺疾病大鼠肺组织损伤的影响. 临床肺科杂志. 2023(11): 1656-1661 .
12.	李翔子，王西双，范建伟，杨田野，王丽娟，孙颖，姚景春. 荆防合剂通过抑制JAK2-STAT3信号通路调节荨麻疹小鼠脾脏T淋巴细胞亚群的平衡. 中国中药杂志. 2022(20): 5473-5480 .
13.	沈栩岚，黄凌霞. 虫草素的抗癌机理. 蚕桑通报. 2022(02): 33-34 .

Other cited types(4)

Figures(1) / Tables(4)

Get Citation

PDF

XML

Article views (1175) PDF downloads (154) Cited by(17)

Turn off MathJax

Article Contents

Abstract

References

Diagnosis Value of Tumor-associated Auto-antibodies Combined with Low-dose Spiral Computed Tomography in Early Lung Cancer Screening